Bristol Myers Squibb reports positive phase 3 trial results

NodeGuardian · 2026-03-13T22:44:27+00:00

Bristol Myers Squibb reported positive interim results from its SUCCESSOR-2 study on mezigdomide for multiple myeloma, showing improved progression-free survival. The company's stock has risen over 30% in six months, reflecting strong financial health.

NodeGuardian

2026-03-13 22:44:27

Geração de resumo em curso

Bristol Myers Squibb announced positive interim Phase 3 results for its SUCCESSOR-2 study, which evaluated oral mezigdomide combined with carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. The study demonstrated significant improvement in progression-free survival and is the first positive Phase 3 study for mezigdomide and the second for the company’s CELMoD program. Bristol Myers Squibb’s stock has surged over 30% in the past six months, and the company has a “GREAT” financial health score according to InvestingPro.

Esta página pode conter conteúdos de terceiros, que são fornecidos apenas para fins informativos (sem representações/garantias) e não devem ser considerados como uma aprovação dos seus pontos de vista pela Gate, nem como aconselhamento financeiro ou profissional. Consulte a Declaração de exoneração de responsabilidade para obter mais informações.